{
    "clinical_study": {
        "@rank": "26898", 
        "acronym": "DIAB-01", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide  endovenous 6 mg", 
                "arm_group_type": "Experimental", 
                "description": "Liraglutide endovenous de 0.6 mg.  one time a day"
            }, 
            {
                "arm_group_label": "Vitamine C", 
                "arm_group_type": "Experimental", 
                "description": "C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients\n      with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes\n      of endothelial function"
        }, 
        "brief_title": "Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Hypoglycemia", 
                "Inflammation"
            ]
        }, 
        "detailed_description": {
            "textblock": "To investigate the effect of antioxidants (Vitamin C) on the vascular damage induced\n      hypoglycemia in patients with type 1 diabetes. The vascular injury was evaluated in the same\n      way as main objective. Checking the existence of a peripheral response to the action of\n      GLP-1 due to oxidative stress."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed and signed consent obtained before any trial-related activity . (\n             Trial-related activities are those procedures that were not performed during routine\n             medical examination of the patient) .\n\n          -  Diagnosis of type 1 diabetes.\n\n          -  Patients who do not have autonomic dysfunction , defined by ( 1).\n\n          -  Patients not showing episodes of hypoglycemia unawareness based on the methods of\n             Gold et al (2) .\n\n          -  Patients without microvascular complications of diabetes.\n\n          -  Patients without macrovascular complications of diabetes.\n\n          -  Patients treated with multiple daily injections of insulin.\n\n          -  No smoking .\n\n          -  They should have a complete blood count, lipid profile, liver profile , renal profile\n             and plasma electrolyte levels within normal values .\n\n          -  No subject must have a history of hypertension or taking medication for high blood\n             pressure .\n\n          -  No subject should be taking medications known to affect the neuroendocrine responses\n             to hypoglycemia or anti inflammatory\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to study some related products.\n\n          -  Fertile women, lactating or pregnant, intend to become pregnant or who are not using\n             adequate contraception, or men who have sexually active and are not sterilized\n             surgically, those whose partners are not using a method adequate contraception.\n\n          -  Clinical diagnosis of Type 2 Diabetes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109315", 
            "org_study_id": "DIAB-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamine C", 
                "description": "C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min", 
                "intervention_name": "Vitamine C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liraglutide  endovenous 6 mg", 
                "description": "Liraglutide endovenous de 0.6 mg. one time a day", 
                "intervention_name": "Liraglutide 6 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ascorbic Acid", 
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocopherols", 
                "Tocotrienols", 
                "Vitamins", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Anna Cruceta", 
                "phone": "932275400", 
                "phone_ext": "4380"
            }, 
            "contact_backup": {
                "last_name": "Anna Cruceta", 
                "phone": "932275400"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Clinic i Provincial de Barcelona"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.", 
        "overall_contact": {
            "email": "acruceta@clinic.ub.es", 
            "last_name": "Anna Cruceta M Cruceta, MD", 
            "phone": "932275400", 
            "phone_ext": "4380"
        }, 
        "overall_contact_backup": {
            "email": "jmleon@clinic.ub.es", 
            "last_name": "CTU Cl\u00ednic (Clinical trial Unit) C Hospital Cl\u00ednic", 
            "phone": "932275400", 
            "phone_ext": "4380"
        }, 
        "overall_official": {
            "affiliation": "Hospital cl\u00ednic i provincial de Barcelona", 
            "last_name": "Antonio Ceriello A Ceriello, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed  measuring flow-mediated vasodilation (FMD) of the brachial artery.", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109315"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3 Cl\u00ednic per la Recerca Biom\u00e8dica", 
            "investigator_full_name": "Anna Cruceta", 
            "investigator_title": "Project manager", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Oxidative stress markers (nitrotyrosine and 8-iso prostaglandin F2 alpha plasma) in serum1 inflammation markers (serum sICAM-1, interleukin 6) 1", 
            "measure": "Oxidative stress markers", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Fundacion Clinic per a la Recerca Biom\u00e9dica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anna Cruceta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}